Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06595238 · ClinicalTrials.gov registry record · Phase 2
A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 262
- Enrollment target
NCT06595238 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 262 participants.
The verdict
NCT06595238, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 262 participants
- Enrollment target
Study Summary
A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 compared with placebo, given once a week as subcutaneous injection for 36 weeks, in male and female participants of at least 18 years of age who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) and at least one weight-related comorbidity
Interventions
- DRUG AZD6234
- DRUG Placebo comparator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 262 participants |
| Start Date | 2024-10-01 |
| Est. Completion | 2025-12-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06595238
The ClinicalTrials.gov registry entry for NCT06595238 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 262 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AZD6234 is the first listed.
NCT06595238 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06595238 about?
NCT06595238 is a clinical study titled "A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity". A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 compared with placebo, given once a week as subcutaneous injection for 36 weeks, in male and female participants of at least 18 years of age who are living with obesity (body m...
What is the current status of trial NCT06595238?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 262 participants. The study started on 2024-10-01. Estimated completion is 2025-12-03.
What interventions are being tested in trial NCT06595238?
The interventions under investigation include: AZD6234 (DRUG), Placebo comparator (DRUG).
Who is sponsoring clinical trial NCT06595238?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.